These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9623098)

  • 1. [Provision of taxoids in 1996: inequality of care].
    Eland IA; Otter R; Krommendijk R; Stricker BH
    Ned Tijdschr Geneeskd; 1998 Mar; 142(10):518-21. PubMed ID: 9623098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Taxoids in ovarian and breast carcinoma: the role of the medical profession and the government].
    Slee PH; Eliel MR; Nortier JW; Rodenburg CJ
    Ned Tijdschr Geneeskd; 1998 Mar; 142(10):502-4. PubMed ID: 9623094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel and docetaxel in breast and ovarian cancer.
    Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
    Lister-Sharp D; McDonagh MS; Khan KS; Kleijnen J
    Health Technol Assess; 2000; 4(17):1-113. PubMed ID: 11074389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The taxoids: paclitaxel and docetaxel.
    Gelmon K
    Lancet; 1994 Nov; 344(8932):1267-72. PubMed ID: 7967989
    [No Abstract]   [Full Text] [Related]  

  • 6. The taxoids. Comparative clinical pharmacology and therapeutic potential.
    Eisenhauer EA; Vermorken JB
    Drugs; 1998 Jan; 55(1):5-30. PubMed ID: 9463787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel and docetaxel. Innovation, but at what cost?
    Lønning PE
    Pharmacoeconomics; 1995 Jul; 8(1):1-4. PubMed ID: 10155597
    [No Abstract]   [Full Text] [Related]  

  • 8. Taxoids.
    Kaye SB
    Eur J Cancer; 1995; 31A(5):824-6. PubMed ID: 7640068
    [No Abstract]   [Full Text] [Related]  

  • 9. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB; Valero V; Hortobagyi G
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Taxanes in the treatment of breast and ovarian cancers: current indications and results].
    Espié M; Cuvier C; Gorins A; Marty M
    Contracept Fertil Sex; 1998 Nov; 26(11):805-11. PubMed ID: 9864888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxoids: effective agents in anthracycline-resistant breast cancer.
    Ravdin PM
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):29-34. PubMed ID: 8604450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taxoid compounds in breast cancer: current status and future prospects.
    Piccart MJ
    Cancer Treat Res; 1995; 78():185-207. PubMed ID: 8595143
    [No Abstract]   [Full Text] [Related]  

  • 13. Taxoids: new weapons against cancer.
    Nicolaou KC; Guy RK; Potier P
    Sci Am; 1996 Jun; 274(6):94-8. PubMed ID: 8643952
    [No Abstract]   [Full Text] [Related]  

  • 14. Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects.
    D'Andrea GM; Seidman AD
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-27-S13-44. PubMed ID: 9335514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
    Leung PP; Tannock IF; Oza AM; Puodziunas A; Dranitsaris G
    J Clin Oncol; 1999 Oct; 17(10):3082-90. PubMed ID: 10506603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer treatments rationed by authority.
    Halle M
    BMJ; 1996 Sep; 313(7060):774. PubMed ID: 8842067
    [No Abstract]   [Full Text] [Related]  

  • 17. Docetaxel.
    Leahy M; Howell A
    Br J Hosp Med; 1997 Feb 19-Mar 4; 57(4):141-4. PubMed ID: 9166374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer.
    Dranitsaris G; Elia-Pacitti J; Cottrell W
    Pharmacoeconomics; 2004; 22(6):375-87. PubMed ID: 15099123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.
    Lamb HM; Wiseman LR
    Pharmacoeconomics; 1998 Oct; 14(4):447-59. PubMed ID: 10344911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The taxanes: an update.
    Crown J; O'Leary M
    Lancet; 2000 Apr; 355(9210):1176-8. PubMed ID: 10791395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.